Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of 2025. The company announced a net loss of approximately $1.1 million for the three months ended March 31, 2025, compared to a net loss of approximately $1.3 million for the same period in 2024. General and administrative expenses decreased to approximately $0.6 million, from approximately $0.8 million in the previous year, primarily due to a reduction in professional services expenses. The company's financial income, net, increased to approximately $0.2 million, compared to $0.1 million in the first quarter of 2024. As of March 31, 2025, Galmed's cash and cash equivalents, including short-term deposits, restricted cash, and marketable debt securities, totaled approximately $15.9 million, up from $15.4 million at the end of 2024. The company also raised an additional $5.0 million in May 2025, bringing its current cash balance to approximately $20.1 million. In terms of business updates, Galmed announced first-time results in oncology studies, indicating that Aramchol significantly enhances Bayer's Regorafenib effect in gastrointestinal cancer models. The company also signed a term sheet for the development of a novel semaglutide sublingual formulation. Additionally, Galmed has raised $6.5 million since the beginning of 2025.